Company Monitoring Page for Acorda-Therapeutics

latest headlines for company on cafepharma

Novartis MS Pill Wins European Backing as Rival Acorda Rejected
Bloomberg
Fri, 01/21/11 - 10:11 am
Tags:
Novartis, MS, multiple sclerosis, Europe, Acorda Therapeutics, Gilenya, Merck KGaA
The FDA approvals of 2010
Fierce Biotech
Wed, 01/12/11 - 07:24 pm
Tags:
Watson Pharmaceuticals, Theratechnologies, Shire, Savient, Sanofi, Roche, Orphan Europe, Novo Nordisk, Novartis, Merz, JNJ, HRA Pharma, Genzyme, Forest Labs, FDA, Eisai, Dainippon Sumitomo, Chemiche Fabrik Kresussler, Boehringer Ingelheim, Bayer, Auxilium, Amgen, Allergan, Acorda Therapeutics
Acorda swings to 3Q profit due to MS drug
Yahoo/AP
Mon, 11/1/10 - 07:55 pm
Tags:
earnings, Acorda Therapeutics
The 3 Words Every Biotech Investor Wants to Hear
Motley Fool
Thu, 10/28/10 - 11:00 am
Tags:
biotech, Acorda Therapeutics, Elan, JNJ, Biogen Idec
Acorda Hopes to Meet Huge Need in Challenging Stroke Market
Seeking Alpha
Thu, 10/21/10 - 11:16 am
Tags:
Acorda Therapeutics, Athersys
These Are the Top 10 Pharma Underperform Calls
Motley Fool
Thu, 08/26/10 - 08:03 pm
Tags:
Dendreon, Human Genome, Targacept, Vanda, Pharmacyclics, Acorda Therapeutics, MannKind
Biogen Starts Patient Enrollment
Yahoo/Zacks.com
Wed, 05/26/10 - 11:11 am
Tags:
Biogen Idec, Abbott Laboratories, Acorda Therapeutics, daclizumab, Avonex, MS
Acorda Therapeutics, Inc. Q1 2010 Earnings Call Transcript
Seeking Alpha
Sat, 05/1/10 - 10:31 am
Tags:
Acorda Therapeutics
Acorda’s Ampyra Runs Ahead of Other MS Treatments
Minyanville
Wed, 04/14/10 - 01:56 pm
Tags:
MS, Acorda Therapeutics, AMPYRA, multiple sclerosis
Seven Biotech Drugs to Watch in the Second Quarter
BNET Pharma
Tue, 04/13/10 - 10:35 am
Tags:
Acorda Therapeutics, AMPYRA, Cell Therapeutics, pixantrone, Pixuvri, Dendreon, Provenge, InterMune, Esbriet, Pozen, Vimovo, XenoPort, Horizant, Astellas, OSI Pharmaceuticals, Ironwood
Biotech Calendar: Key Dates for April
TheStreet.com
Mon, 04/5/10 - 09:53 am
Tags:
Forest Labs, Celgene, Genzyme, Lexicon Pharmaceuticals, Cell Therapeutics, Acadia, Acorda Therapeutics, Vertex Pharmaceuticals, Indenix, Pozen, Acura Pharmaceuticals, OSI Pharmaceuticals, Cyclacel, Peregrine Pharmaceuticals, Anadys, Pharmasset, Dendreon
Acorda applies to extend Ampyra patent protection
Yahoo/AP
Mon, 03/22/10 - 09:54 am
Tags:
Acorda Therapeutics, patents, AMPYRA, MS, multiple sclerosis
Analyst reiterates 'Market Perform' on Acorda, says value reflects Ampyra launch prospect
Yahoo/AP
Wed, 02/24/10 - 10:11 am
Tags:
Acorda Therapeutics, AMPYRA
2010 FDA Approvals Could Lead to Launch of Eight New Biotech Blockbusters
BNET Pharma
Tue, 02/9/10 - 10:58 am
Tags:
FDA, Cadence Pharmaceuticals, Acorda Therapeutics, Auxilium, Gilead Sciences, Shire, Amylin, Cell Therapeutics, Dendreon, InterMune, Amgen, Human Genome, NicOx, Vivus, Arena Pharmaceuticals, Orexigen
4 Winning Biotechs For Your Portfolio: Senior Analyst
CNBC
Mon, 02/8/10 - 12:30 pm
Tags:
Amgen, Gilead Sciences, Dendreon, Acorda Therapeutics
Acorda's MS Drug May Not Be the Windfall Investors Expect
Seeking Alpha
Wed, 01/27/10 - 10:57 am
Tags:
Acorda Therapeutics, MS, multiple sclerosis, Biogen Idec, AMPYRA
Acorda: After FDA Approval, What's Next for Ampyra?
Seeking Alpha
Tue, 01/26/10 - 08:54 am
Tags:
AMPYRA, Acorda Therapeutics
Debunking the Accorda Therapeutics Merger Rumors
BNET Pharma
Mon, 01/25/10 - 12:36 pm
Tags:
Acorda Therapeutics, M&A, Biogen Idec, Teva Pharmaceuticals, AMPYRA
What the New MS Drug (AMPYRA) Does (and What It Doesn’t Do)
Wall Street Journal
Sat, 01/23/10 - 10:51 am
Tags:
Acorda Therapeutics, AMPYRA, multiple sclerosis
Acorda Therapeutics Announces FDA Approval of AMPYRA (dalfampridine) to Improve Walking in People with Multiple Sclerosis - Demonstrated by Increases in Walking Speed
Yahoo/Business Wire
Sat, 01/23/10 - 10:48 am
Tags:
Acorda Therapeutics, AMPYRA, multiple sclerosis

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.